Truist Securities initiated coverage on Revolution Medicines (RVMD) with a buy rating and a $179 price target.
The stock currently trades at $145.66, up 268% over the past year. Market cap stands at $31 billion.
Analysts see daraxon as a leading candidate for RAS-mutant cancers, potentially capturing over 70% of the pancreatic ductal adenocarcinoma market.
According to Bond.az, the company's strong trial footprint and high efficacy barrier create a durable competitive advantage.
Upcoming ASCO data could reinforce momentum ahead of a likely near-term second-line approval for pancreatic cancer.
Revolution Medicines focuses on targeted oncology therapies for RAS-mutant cancers.
